iBio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by iBio, Inc. on February 19, 2025. The filing addresses a corporate action regarding the transfer of the listing of the Company's common stock from one exchange to another.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing status and does not contain financial performance data.
Material Changes
The primary material change is the voluntary withdrawal of the Company's common stock listing from NYSE American LLC and its transfer to The Nasdaq Capital Market. The Board of Directors authorized this action on February 19, 2025.
Outlook and Management Commentary
Management has confirmed the timeline for the exchange transfer. Trading on NYSE American is expected to conclude at market close on March 3, 2025. Trading on Nasdaq is scheduled to commence at market open on March 4, 2025. The ticker symbol "IBIO" will remain unchanged during and after the transfer. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the exact date trading ceases on NYSE American (March 3, 2025).
- Confirm the start date for trading on Nasdaq (March 4, 2025).
- Ensure the ticker symbol remains "IBIO" post-transfer.
- Review the press release filed as Exhibit 99.1 for additional context on the listing transfer.